04 Jul , 2025 By : Debdeep Gupta
Shares of pharma player Emcure Pharmaceuticals Ltd sank two percent on Friday, July 4, after a large deal took place in the block deal window.
Around 45.51 lakh shares or 2.4 percent equity worth Rs 574 crore changed hands at Rs 1,262 apiece. At 9.25 a.m., shares were quoting Rs 1,255, down two percent.
Bain Capital-backed BC Investments IV might offload a 2.4 percent stake in the firm for Rs 551 crore, according to sources. The floor price for the deal is set at Rs 1,279.80 per share, which comes as a discount to the previous session's closing price. Kotak Securities is the lead manager for this deal.
According to the March quarter shareholding update, the promoters in the firm own around 77.9 percent, while FIIs and DIIs hold 3.1 percent and 3.4 percent, respectively. The public shareholding in the firm is 15.6 percent.
The company reported a 64.4 percent year-on-year (YoY) increase in net profit, which rose to Rs 189 crore in the fourth quarter of FY25, up from Rs 115 crore in the same period last year. The company's revenue also posted a strong growth of 19.5 percent YoY, climbing to Rs 2,116 crore, compared to Rs 1,771.3 crore in Q4FY24, reflecting sustained demand across key markets.
The company's total income rose to Rs 2,121 crore for the quarter under review, against Rs 1,784 crore in the year ago period. The expenses of the company also rose to Rs 1,850 crore in Q4FY25, compared to Rs 1,617 crore in Q4FY24.
Emcure made its market debut in July 2024, raising Rs 1,951 crore through its IPO, which comprised a fresh issue of Rs 800 crore and an offer for sale (OFS) worth Rs 1,151 crore. Listed at Rs 1,008 per share, the stock is currently trading around 27 percent above its issue price.
Emcure shares have declined 4 percent over the past month and are down nearly 13 percent so far in 2025. The stock currently trades 19 percent below its record high of Rs 1,580, touched in September 2024.
0 Comment